SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum.
Ratings
0 / 5
0 ratings in the last 12 months
5
4
3
2
1
CEO
Dr. Eddie J. Sullivan, PhD$45M
Market Cap • 16/04/20242014
(há 10 anos)
2021
(3 years ago)
NASDAQ
Listagem
Sioux Falls
Sede • South Dakota56
N° de Empregados • 2022Valuation
Company FinancialsValuation Indicators
Valuation IndicatorsRetorno Histórico
SABSSó no Premium...
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.